Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Scilex Holding Company ( (SCLX) ).
On September 21, 2023, Scilex Holding Company issued to Oramed Pharmaceuticals 6.5 million penny warrants to purchase Scilex common stock at $0.01 per share, and on July 22, 2025, it entered into an option agreement allowing Scilex to repurchase those warrants in two tranches for a total of $27 million, in exchange for a $1.5 million fee paid to Oramed for granting the option. On December 30, 2025, Scilex completed the full exercise of this option by paying the remaining $14 million to repurchase the second tranche of warrants, after having repurchased the first tranche for $13 million in September 2025, effectively eliminating the highly dilutive low‑exercise‑price warrants and potentially improving its capital structure for existing shareholders.
The most recent analyst rating on (SCLX) stock is a Buy with a $770.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company operates in the pharmaceutical sector, focusing on the development and commercialization of specialty pharmaceutical products, particularly in pain management and related therapeutic areas.
Average Trading Volume: 156,079
Technical Sentiment Signal: Sell
Current Market Cap: $116.2M
Learn more about SCLX stock on TipRanks’ Stock Analysis page.